Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 10/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 5/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL703244 | 0.81 | KIF11 (0.46) | KIF11FFAR1PDE2AAKR1C3AKR1C2 | |
| SCHEMBL28196330 | 0.81 | KIF11 (0.46) | KIF11FFAR1KDM1ATRPM8PDE2A | |
| SCHEMBL18285740 | 0.79 | PDE2A (0.50) | KIF11FFAR1PDE2AAKR1C3AKR1C2 | |
| SCHEMBL18283155 | 0.78 | KIF11 (0.43) | KIF11FFAR1PDE2A | |
| SCHEMBL19136345 | 0.78 | KIF11 (0.43) | KIF11FFAR1PDE2AAKR1C3AKR1C2 | |
| SCHEMBL1539015 | 0.78 | PDE2A (0.46) | KIF11FFAR1KDM1APDE2AAKR1C3 | |
| SCHEMBL1759520 | 0.77 | CES2 (0.50) | AKR1C3AKR1C2 | |
| SCHEMBL16660435 | 0.77 | KIF11 (0.42) | KIF11FFAR1KDM1ATRPM8PDE2A | |
| SCHEMBL18290662 | 0.77 | PDE2A (0.49) | KIF11FFAR1PDE2AAKR1C3AKR1C2 | |
| SCHEMBL8146090 | 0.76 | KIF11 (0.48) | KIF11FFAR1KDM1APDE2AAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103635472-B | Serine/threonine kinase inhibitor | 阵列生物制药公司 | 2018-01-12 | — | — | CN | disclosed |